AIM:BXP

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products, intravenous fluids, and active pharmaceutical ingredients in Bangladesh. More Details


Snowflake Analysis

Solid track record with excellent balance sheet.


Similar Companies

Share Price & News

How has Beximco Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BXP's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.9%

BXP

-2.3%

GB Pharmaceuticals

-0.3%

GB Market


1 Year Return

68.6%

BXP

-3.4%

GB Pharmaceuticals

-16.6%

GB Market

Return vs Industry: BXP exceeded the UK Pharmaceuticals industry which returned 0.4% over the past year.

Return vs Market: BXP exceeded the UK Market which returned -16.2% over the past year.


Shareholder returns

BXPIndustryMarket
7 Day0.9%-2.3%-0.3%
30 Day8.3%-7.6%0.7%
90 Day34.5%-9.4%-3.4%
1 Year73.1%68.6%0.1%-3.4%-13.4%-16.6%
3 Year4.4%-1.7%41.2%25.5%-9.6%-20.8%
5 Year227.9%197.8%67.5%34.7%14.5%-11.3%

Price Volatility Vs. Market

How volatile is Beximco Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Beximco Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

13.7x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: BXP (£0.59) is trading above our estimate of fair value (£0.32)

Significantly Below Fair Value: BXP is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BXP is good value based on its PE Ratio (13.7x) compared to the GB Pharmaceuticals industry average (17.4x).

PE vs Market: BXP is good value based on its PE Ratio (13.7x) compared to the UK market (18.1x).


Price to Earnings Growth Ratio

PEG Ratio: BXP is good value based on its PEG Ratio (0.9x)


Price to Book Ratio

PB vs Industry: BXP is good value based on its PB Ratio (1.5x) compared to the GB Pharmaceuticals industry average (4.5x).


Next Steps

Future Growth

How is Beximco Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

14.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BXP's forecast earnings growth (14.6% per year) is above the savings rate (1.2%).

Earnings vs Market: BXP's earnings (14.6% per year) are forecast to grow slower than the UK market (24.1% per year).

High Growth Earnings: BXP's earnings are forecast to grow, but not significantly.

Revenue vs Market: BXP's revenue (10.7% per year) is forecast to grow faster than the UK market (6% per year).

High Growth Revenue: BXP's revenue (10.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BXP's Return on Equity is forecast to be low in 3 years time (12.2%).


Next Steps

Past Performance

How has Beximco Pharmaceuticals performed over the past 5 years?

13.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BXP has high quality earnings.

Growing Profit Margin: BXP's current net profit margins (13.7%) are higher than last year (13.1%).


Past Earnings Growth Analysis

Earnings Trend: BXP's earnings have grown by 13.5% per year over the past 5 years.

Accelerating Growth: BXP's earnings growth over the past year (20%) exceeds its 5-year average (13.5% per year).

Earnings vs Industry: BXP earnings growth over the past year (20%) exceeded the Pharmaceuticals industry 9.8%.


Return on Equity

High ROE: BXP's Return on Equity (10.8%) is considered low.


Next Steps

Financial Health

How is Beximco Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: BXP's short term assets (BDT13.1B) exceed its short term liabilities (BDT12.3B).

Long Term Liabilities: BXP's short term assets (BDT13.1B) exceed its long term liabilities (BDT5.9B).


Debt to Equity History and Analysis

Debt Level: BXP's debt to equity ratio (35%) is considered satisfactory.

Reducing Debt: BXP's debt to equity ratio has increased from 20.5% to 35% over the past 5 years.

Debt Coverage: BXP's debt is well covered by operating cash flow (38.7%).

Interest Coverage: BXP's interest payments on its debt are well covered by EBIT (5.2x coverage).


Balance Sheet


Next Steps

Dividend

What is Beximco Pharmaceuticals's current dividend yield, its reliability and sustainability?

1.30%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: BXP's dividend (1.3%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.82%).

High Dividend: BXP's dividend (1.3%) is low compared to the top 25% of dividend payers in the UK market (5.3%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, BXP has been paying a dividend for less than 10 years.

Growing Dividend: BXP's dividend payments have increased, but the company has only paid a dividend for 6 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (17.8%), BXP's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: BXP's dividends in 3 years are forecast to be well covered by earnings (25.3% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

11.4yrs

Average management tenure


CEO

Nazmul Hassan

11.42yrs

Tenure

Mr. Nazmul Hassan, MP has been the Managing Director at Beximco Pharmaceuticals Limited since May 2009. Mr. Hassan served as the Managing Director of Shinepukur Ceramics Limited until November 14, 2013. Pr ...


Leadership Team

NamePositionTenureCompensationOwnership
Nazmul Hassan
MD & Director11.42yrsno datano data
Mohammad Nawaz
Chief Financial Officerno datano datano data
Rabbur Reza
Chief Operating Officer11.42yrsno datano data
Jamal Choudhury
Executive Director of Accounts & Financeno datano datano data
M. Bhuiyan
Deputy General Manager of Human Resourcesno datano datano data
Mohammad Ullah
Company Secretary & Executive Directorno datano datano data
Zakaria Chowdhury
Director of International Marketing10.75yrsno datano data
Prabir Ghose
Executive Director of Quality Assuranceno datano datano data
Rizvi Kabir
Director of Marketingno datano datano data

11.4yrs

Average Tenure

Experienced Management: BXP's management team is seasoned and experienced (11.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Beximco Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Beximco Pharmaceuticals Limited
  • Ticker: BXP
  • Exchange: AIM
  • Founded: 1976
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ৳46.923b
  • Listing Market Cap: ৳422.632m
  • Shares outstanding: 405.56m
  • Website: https://www.beximcopharma.com

Number of Employees


Location

  • Beximco Pharmaceuticals Limited
  • 19 Dhanmondi R/A
  • Road No. 7
  • Dhaka
  • 1205
  • Bangladesh

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BXPHARMADSE (Dhaka Stock Exchange Ltd.)YesOrdinary SharesBDBDTApr 1996
BXPAIM (London Stock Exchange AIM Market)SPON GDR REP ONE ORD SH OF TAKA 10 REG SGBGBPOct 2005
R2WADB (Deutsche Boerse AG)SPON GDR REP ONE ORD SH OF TAKA 10 REG SDEEUROct 2005
R2WABST (Boerse-Stuttgart)SPON GDR REP ONE ORD SH OF TAKA 10 REG SDEEUROct 2005

Biography

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products, intravenous fluids, and active pharmaceutical ingredients in Bangladesh. The company offers allergic di ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/22 20:41
End of Day Share Price2020/10/21 00:00
Earnings2020/03/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.